Rabinowitz Matthew sold $16.4M of NTRA

Rabinowitz Matthew (EXECUTIVE CHAIRMAN) sold 50,000 shares of Natera, Inc. (NTRA) at an average of $327.97 ($325.01–$329.62, $16.40M total) across 6 trades on 2026-09-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Rabinowitz Matthew
Published Sep 12, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 12, 2026, 2:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Bearish
medium confidence
Mentioned
$NTRA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRABearishLow
01

Why it matters

The disclosed sale is the first public report of this transaction, making it a primary source of new information.

02

Market read

Insider sell of this size may prompt short‑term price pressure, but the pre‑arranged nature tempers the signal.

03

What to watch

The 10b5‑1 plan indicates pre‑planned execution, reducing the informational weight of the sale.

Relevance 6/10Novelty 7/10Timing: after-market 2026-09-11

Background

Form 4 filings disclose insider transactions; a 10b5‑1 plan allows pre‑scheduled sales.

Company-level read

Ticker impact

$NTRABearishMedium confidence
Context

Executive Chairman Matthew Rabinowitz sold 50,000 shares for $16.4M via a 10b5‑1 plan, reducing his stake to 2,225,394 shares.

Expected impact

Possible modest downside pressure over the next few days.

Evidence & confidence

A $16M sale by a top executive is material and disclosed first via Form 4; markets often react negatively to sizable insider disposals.

Market effects

Minimal; biotech sector may see slight sentiment drag from insider sell.

U.S. market only; no broader regional effect.

Low; limited to Natera investors.

Counterpoint

The sale could be a routine liquidity event under a pre‑arranged plan, not a negative signal.

Key entities

  • Matthew Rabinowitz

    Executive Chairman of Natera, Inc.

  • Natera, Inc.

    Genomics testing company listed on NASDAQ.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

What's Next for Colorectal Cancer? A Major Announcement at OncoDaily

Natera announced a partnership with Agenus to use Signatera ctDNA testing in the Phase III ROBIN trial for colorectal cancer. The trial will compare neoadjuvant immunotherapy plus surgery to upfront surgery. Dr. Robert Lentz, Natera's Medical Director, highlighted the potential of ctDNA testing in treatment evaluation and decision-making.

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.